Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 08 - 08 symbols : Lly save search
Global Oncology Drugs Market to Surpass US$ 301.8 Billion by 2030 - Coherent Market Insights
Published: 2022-08-08 (Crawled : 18:00) - prnewswire.com
AZNCF | News | $140.3 1.5K
|
Health Technology
|
| O: 4.04%
H: 0.0%
C: 0.0%
MCK | $535.46 0.65% 190K
|
Distribution Services
|
| O: 0.07%
H: 0.84%
C: 0.12%
JNJ | News | $148.515 -0.7% 4.3M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
SNY | News | $46.765 -1.94% 950K
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
AZN | News | $71.26 0.58% 3.8M
|
Health Technology
|
| O: -0.53%
H: 0.49%
C: -0.85%
AMGN | News | $274.15 0.22% 900K
|
Health Technology
|
| O: -0.51%
H: 1.12%
C: 0.93%
global market
Glioma Pipeline Insights | Clinical Trial Research Evaluation Report By DelveInsight
Published: 2022-08-08 (Crawled : 16:00) - prnewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
INCY | $51.76 0.21% 600K
|
Health Technology
|
| O: 0.0%
H: 2.7%
C: 2.55%
research report trial
Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory AffairsBrings 30 Years of Experience as a Former Endocyte and Novartis Regulatory Executive
Published: 2022-08-08 (Crawled : 12:00) - biospace.com/
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
CMRX | $0.9033 -2.38% 70K
|
Health Technology
|
| O: 7.46%
H: 0.63%
C: -18.06%
novartis
Insulin Market Size Worth $111.21 Billion by 2028 at 10.8% CAGR Lead by Biosimilar Insulin Segment (Register 16% CAGR) Global Analysis by The Insight Partners
Published: 2022-08-08 (Crawled : 12:00) - prnewswire.com
GSK | News | $40.905 -0.81% 890K
|
Health Technology
|
| O: -0.02%
H: 0.24%
C: -0.62%
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
SNY | News | $46.765 -1.94% 950K
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
global biosimilar insulin market
Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience
Published: 2022-08-08 (Crawled : 11:00) - prnewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
taltz injection
Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema
Published: 2022-08-08 (Crawled : 01:00) - prnewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
SNY | News | $46.765 -1.94% 950K
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
INCY | $51.76 0.21% 600K
|
Health Technology
|
| O: 0.0%
H: 2.7%
C: 2.55%
ibi324 macular study diabetic phase 1
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
Published: 2022-08-08 (Crawled : 01:00) - globenewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
HCM | $18.34 0.49% 38K
|
Health Technology
|
| O: 3.03%
H: 5.21%
C: -2.59%
BGNE | $143.7 3.39% 120K
|
Health Technology
|
| O: 2.38%
H: 3.38%
C: 1.58%
global cancer study
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.85 51.79% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
MULN | News | $3.805 39.38% 11M
|
Information
RILY | $30.01 38.17% 11M
|
Finance
MTC | $3.04 35.71% 6.7M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.